In situ real-time tracing of hierarchical targeting nanostructures in drug resistant tumors using diffuse fluorescence tomography-Reference-Cited by-同舟云学术

In situ real-time tracing of hierarchical targeting nanostructures in drug resistant tumors using diffuse fluorescence tomography

Published:2019 Issue:34 Volume:10 Page:7878-7886
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Guo Qianqian¹²³⁴⁵,Wang Yangyun⁶⁷⁸⁹¹⁰,Zhang Limin¹¹¹²¹³¹⁴,Zhang Peng¹⁵¹⁶¹⁷¹⁸^ORCID,Yu Yunjian¹²³⁴⁵,Zhang Yanqi¹¹¹²¹³¹⁴,Li Chaoxing¹²³⁴⁵,Jiang Shaoyi¹⁵¹⁶¹⁷¹⁸,Zhang Xinge¹²³⁴⁵^ORCID

Affiliation:

1. Key Laboratory of Functional Polymer Materials of Ministry of Education

2. Institute of Polymer Chemistry

3. College of Chemistry

4. Nankai University

5. Tianjin 300071

6. State Key Laboratory of Radiation Medicine and Protection

7. School for Radiological & Interdisciplinary Sciences (RAD-X)

8. Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions

9. Soochow University

10. Suzhou 215123

11. College of Precision Instrument and Optoelectronics Engineering

12. Tianjin University

13. Tianjin 300072

14. China

15. Department of Chemical Engineering

16. University of Washington

17. Seattle

18. USA

Abstract

Nanoparticles that respond to specific endogenous or exogenous stimuli in tumor tissues are actively being developed to address multidrug resistance owing to multiple advantages, including a prolonged circulation time, enhanced permeability and retention effect, and superior cellular uptake.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/SC/C9SC01841G

Reference52 articles.

1. Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo

2. Size Changeable Nanocarriers with Nuclear Targeting for Effectively Overcoming Multidrug Resistance in Cancer Therapy

3. Therapeutic Nanoparticles for Drug Delivery in Cancer